India · Delayed Price · Currency is INR Concord Biotech Statistics
Total Valuation
Concord Biotech has a market cap or net worth of INR 126.27 billion. The enterprise value is 121.79 billion.
| Market Cap | 126.27B |
| Enterprise Value | 121.79B |
Important Dates
The last earnings date was Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | Jul 24, 2026 |
Share Statistics
Concord Biotech has 209.23 million shares outstanding. The number of shares has increased by 0.25% in one year.
| Current Share Class | 209.23M |
| Shares Outstanding | 209.23M |
| Shares Change (YoY) | +0.25% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 60.87% |
| Owned by Institutions (%) | 15.69% |
| Float | 53.24M |
Valuation Ratios
The trailing PE ratio is 44.93 and the forward PE ratio is 32.93. Concord Biotech's PEG ratio is 1.16.
| PE Ratio | 44.93 |
| Forward PE | 32.93 |
| PS Ratio | 10.79 |
| PB Ratio | 6.09 |
| P/TBV Ratio | 6.10 |
| P/FCF Ratio | 69.24 |
| P/OCF Ratio | 44.46 |
| PEG Ratio | 1.16 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 29.32, with an EV/FCF ratio of 66.78.
| EV / Earnings | 43.12 |
| EV / Sales | 10.41 |
| EV / EBITDA | 29.32 |
| EV / EBIT | 35.76 |
| EV / FCF | 66.78 |
Financial Position
The company has a current ratio of 6.40, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.40 |
| Quick Ratio | 4.25 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | 0.01 |
| Interest Coverage | 1,448.60 |
Financial Efficiency
Return on equity (ROE) is 14.33% and return on invested capital (ROIC) is 15.85%.
| Return on Equity (ROE) | 14.33% |
| Return on Assets (ROA) | 9.79% |
| Return on Invested Capital (ROIC) | 15.85% |
| Return on Capital Employed (ROCE) | 16.04% |
| Weighted Average Cost of Capital (WACC) | 6.68% |
| Revenue Per Employee | 7.21M |
| Profits Per Employee | 1.74M |
| Employee Count | 1,624 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.26 |
Taxes
In the past 12 months, Concord Biotech has paid 946.78 million in taxes.
| Income Tax | 946.78M |
| Effective Tax Rate | 25.31% |
Stock Price Statistics
The stock price has decreased by -16.96% in the last 52 weeks. The beta is 0.44, so Concord Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | -16.96% |
| 50-Day Moving Average | 683.60 |
| 200-Day Moving Average | 632.08 |
| Relative Strength Index (RSI) | 41.59 |
| Average Volume (20 Days) | 319,802 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Biotech had revenue of INR 11.70 billion and earned 2.82 billion in profits. Earnings per share was 13.43.
| Revenue | 11.70B |
| Gross Profit | 7.45B |
| Operating Income | 3.41B |
| Pretax Income | 3.74B |
| Net Income | 2.82B |
| EBITDA | 4.14B |
| EBIT | 3.41B |
| Earnings Per Share (EPS) | 13.43 |
Balance Sheet
The company has 4.46 billion in cash and 17.50 million in debt, with a net cash position of 4.44 billion or 21.22 per share.
| Cash & Cash Equivalents | 4.46B |
| Total Debt | 17.50M |
| Net Cash | 4.44B |
| Net Cash Per Share | 21.22 |
| Equity (Book Value) | 20.72B |
| Book Value Per Share | 97.69 |
| Working Capital | 10.89B |
Cash Flow
In the last 12 months, operating cash flow was 2.84 billion and capital expenditures -1.02 billion, giving a free cash flow of 1.82 billion.
| Operating Cash Flow | 2.84B |
| Capital Expenditures | -1.02B |
| Depreciation & Amortization | 728.97M |
| Net Borrowing | 1.43M |
| Free Cash Flow | 1.82B |
| FCF Per Share | 8.72 |
Margins
Gross margin is 63.65%, with operating and profit margins of 29.12% and 24.13%.
| Gross Margin | 63.65% |
| Operating Margin | 29.12% |
| Pretax Margin | 31.96% |
| Profit Margin | 24.13% |
| EBITDA Margin | 35.35% |
| EBIT Margin | 29.12% |
| FCF Margin | 15.58% |
Dividends & Yields
This stock pays an annual dividend of 3.78, which amounts to a dividend yield of 0.63%.
| Dividend Per Share | 3.78 |
| Dividend Yield | 0.63% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 27.97% |
| FCF Payout Ratio | 43.31% |
| Buyback Yield | -0.25% |
| Shareholder Yield | 0.38% |
| Earnings Yield | 2.23% |
| FCF Yield | 1.44% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Concord Biotech is 760.50, which is 26.02% higher than the current price. The consensus rating is "Buy".
| Price Target | 760.50 |
| Price Target Difference | 26.02% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 21.37% |
| EPS Growth Forecast (3Y) | 27.78% |
Stock Splits
The last stock split was on November 4, 2026. It was a forward split with a ratio of 2.
| Last Split Date | Nov 4, 2026 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |